A5028249379- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pediatric health and respiratory diseases
- Tracheal and airway disorders
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Respiratory and Cough-Related Research
- Epigenetics and DNA Methylation
- Respiratory Support and Mechanisms
- Asthma and respiratory diseases
- Liver Disease and Transplantation
- Immune cells in cancer
- Liver Disease Diagnosis and Treatment
- Advanced Chemical Sensor Technologies
- Intensive Care Unit Cognitive Disorders
- Gut microbiota and health
- Infant Nutrition and Health
- Pneumonia and Respiratory Infections
- Peptidase Inhibition and Analysis
- High Altitude and Hypoxia
- Inflammatory Bowel Disease
- Congenital Diaphragmatic Hernia Studies
- Immune Response and Inflammation
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2021-2025
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2021-2025
University of Dundee
2023-2025
Universitat de Barcelona
2020-2024
Ninewells Hospital
2023-2024
Hospital Clínic de Barcelona
2021-2023
Fundació Clínic per a la Recerca Biomèdica
2023
Hospital de Sant Pau
2017-2022
Centro de Investigación Biomédica en Red
2021-2022
Universitat Autònoma de Barcelona
2018-2019
Rationale: Bronchiectasis is classically considered a neutrophilic disorder, but eosinophilic subtypes have recently been described. Objectives: To use multiple datasets available through the European Multicentre Audit and Research Collaboration to characterize bronchiectasis as clinical entity focusing on impact of eosinophils exacerbations. Methods: Patients were included from five countries examine relationships between blood eosinophil counts phenotypes after excluding coexisting asthma....
Rationale: The principal underlying inhaled antibiotic treatment in bronchiectasis is that airway bacterial load drives inflammation, and therefore will reduce symptoms. Objectives: To determine the relationship between clinical outcomes, assess stability of over time, test hypothesis response to antibiotics would be predicted by baseline load. Methods: We performed three studies. Studies 1 2 were prospective studies including adults with bronchiectasis. Study 3 was a post hoc analysis...
Some COVID-19 survivors present lung function abnormalities during follow-up, particularly reduced carbon monoxide diffusing capacity (DLCO). To investigate risk factors and underlying pathophysiology, we compared the clinical characteristics levels of circulating pulmonary epithelial endothelial markers in with normal or DLCO 6 months after discharge.
Rationale: Although inflammation and infection are key disease drivers in bronchiectasis, few studies have integrated host inflammatory microbiome data to guide precision medicine. Objectives: To identify clusters among patients with bronchiectasis on the basis of markers assess association between endotypes, characteristics, exacerbation risk. Methods: Patients stable were enrolled at three European centers, cluster analysis was used stratify according levels 33 sputum serum markers....
Guillain-Barré syndrome (GBS) is an acute, immune-mediated flaccid paralysis frequently associated with Campylobacter infection. Of two predominant GBS subtypes, a demyelinating subtype (acute inflammatory demyelinative polyneuropathy [AIDP]) predominates in the United States and Europe, axonal motor neuropathy [AMAN]) form China. Previous clinical studies suggested that AMAN also occurs Mexican children. The purpose of this study was to describe subtypes children from Mexico City.We...
Introduction Neutrophil elastase activity in sputum can identify patients at high risk of airway infection and exacerbations bronchiectasis. Application this biomarker clinical practice is limited, because no point-of-care test available. We tested whether a novel semi-quantitative lateral flow device (neutrophil stick – NEATstik®) stratify bronchiectasis according to severity, exacerbation risk. Methods Sputum samples from 124 with stable enrolled the UK Spain were using NEATstik®, which...
Recently a frequent exacerbator phenotype has been described in bronchiectasis, but the underlying biological mechanisms are unknown. Antimicrobial peptides (AMPs) important host defence against microbes can be proinflammatory chronic lung disease.To determine pulmonary and systemic levels of AMP their relationship with disease severity future risk exacerbations bronchiectasis.A total 135 adults bronchiectasis were prospectively enrolled at three European centres. Levels cathelicidin LL-37,...
Bronchiectasis is characterized by acute exacerbations, but the biological mechanisms underlying these events are poorly characterized.
Rationale The inflammasome is a key regulatory complex of the inflammatory response leading to interleukin-1β (IL-1β) release and activation. IL-1β amplifies responses induces mucus secretion hyperconcentration in other diseases. role bronchiectasis has not been investigated. Objectives To characterise airway bronchiectasis, including association with properties, ciliary function, inflammation, microbiome disease severity. Methods Stable patients were enrolled an international cohort study...
Bronchiectasis is a complex and heterogeneous inflammatory chronic respiratory disease with an unknown cause in around 30–40% of patients. The presence airway infection together inflammation, mucociliary dysfunction lung damage are key components the vicious vortex model that better describes its pathophysiology. Although bronchiectasis research has significantly increased over past years different endotypes have been identified, there still major gaps understanding Genomic approaches may...
Although tacrolimus is recommended by KDIGO Clinical Practice Guideline for Glomerulonephritis the treatment of idiopathic membranous nephropathy (MN), little known about factors that influence response and relapse disease after therapy. Multicentre study collected 122 MN patients with nephrotic syndrome stable renal function treated tacrolimus. Duration was 17.6 ± 7.2 months, including a full-dose tapering period. The percentage remission 60, 78 84% 6, 12 18 months treatment, respectively....
<b><i>Background:</i></b> <i>Pseudomonas aeruginosa</i> (PA) is a common microorganism related to severe exacerbations in Chronic Obstructive Pulmonary Disease (COPD). However, their role COPD patients with frequent hospitalized (FHE) not well described. <b><i>Objectives:</i></b> We aimed determine prevalence, risk factors, susceptibility patterns and impact on outcomes of PA FHE. <b><i>Methods:</i></b>...
Background Recent randomised clinical trials in bronchiectasis have failed to reach their primary end-points, suggesting a need reassess how we measure treatment response. Exacerbations, quality of life (QoL) and lung function are the most common end-points evaluated trials. We aimed determine relationship between responses terms reduced exacerbations, improved symptoms bronchiectasis. Methods response three that mucoactive therapy (inhaled mannitol), an oral anti-inflammatory/antibiotic...
In the WILLOW trial, Dipeptidyl peptidase-1 inhibitor brensocatib reduced neutrophil serine protease (NSP) activity and prolonged time to first exacerbation in patients with bronchiectasis. We hypothesized that, by reducing NSPs, would affect antimicrobial peptides, mucins, cytokines throughout inflammatory cascade. The trial was a phase 2 randomized of (10mg 25mg) versus placebo. Sputum collected at baseline, week 4, 24 (end treatment) 28 (4 weeks post-treatment). peptides secretory...
Respiratory infections are common after strenuous exercise, when salivary immunity may be altered. We aim to investigate changes in a marathon and its relationship with lower respiratory tract (LRTI) healthy non-elite runners.Forty seven runners (28 males 19 females) who completed the 42.195 km of 2016 Barcelona were studied. Saliva blood samples collected day before two days end race. Salivary IgA, antimicrobial proteins (lactoferrin, lysozyme) chemokines (Groα, Groβ, MCP-1) determined...
In this work, breath samples from clinically stable bronchiectasis patients with and without bronchial infections by Pseudomonas Aeruginosa- PA) were collected chemically analysed to determine if they have clinical value in the monitoring of these patients.A cohort was recruited inviting (25) controls (9). Among former group, 12 members suffering PA infection. Breath Tedlar bags analyzed e-nose Gas Chromatography-Mass Spectrometry (GC-MS). The obtained data chemometric methods their...